ArticleCancer cell international2008
A novel and generalizable organotypic slice platform to evaluate stem cell potential for targeting pediatric brain tumors.
Article in Cancer cell international, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Rethinking p16, p53, and HPV in HNCSCC through lessons from glioblastoma subclonal evolution toward patient-centric N-of-1 single-cell RNA sequencing paradigm.World journal of clinical cases · 2025Article
- Recapitulating the immune microenvironment in pediatric brain cancer: preclinical modeling strategies.Frontiers in immunology · 2025Review
- Cancer Niche as a Garbage Disposal Machine: Implications of TCM-Mediated Balance of Body-Disease for Treatment of Cancer.Online journal of complementary & alternative medicine · 2019Article
- Spatiotemporal switching signals for cancer stem cell activation in pediatric origins of adulthood cancer: Towards a watch-and-wait lifetime strategy for cancer treatment.World journal of stem cells · 2018Review
- Tissue elasticity regulated tumor gene expression: implication for diagnostic biomarkers of primitive neuroectodermal tumor.PloS one · 2015Article
- Training stem cells for treatment of malignant brain tumors.World journal of stem cells · 2014Review
- Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor.Cancer cell international · 2014Article
- Cultivating stem cells for treating amyotrophic lateral sclerosis.World journal of stem cells · 2012Article
- Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall.Cancer cell international · 2012Article
- Control dominating subclones for managing cancer progression and posttreatment recurrence by subclonal switchboard signal: implication for new therapies.Stem cells and development · 2012Review
- Mechanisms for progenitor cell-mediated repair for ischemic heart injury.Current stem cell research & therapy · 2012Review
- Convergence of normal stem cell and cancer stem cell developmental stage: Implication for differential therapies.World journal of stem cells · 2011Article
- Increase developmental plasticity of human keratinocytes with gene suppression.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Therapeutic window, a critical developmental stage for stem cell therapies.Current stem cell research & therapy · 2010Review
- A biological global positioning system: considerations for tracking stem cell behaviors in the whole body.Stem cell reviews and reports · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain tumors are now the leading cause of cancer-related deaths in children under age 15. Malignant gliomas are, for all practical purposes, incurable and new therapeutic approaches are desperately needed. One emerging strategy is to use the tumor tracking capacity inherent in many stem cell populations to deliver therapeutic agents to the brain cancer cells. Current limitations of the stem cell therapy strategy include that stem cells are treated as a single entity and lack of uniform technology is adopted for selection of clinically relevant sub-populations of stem cells. Specifically, therapeutic success relies on the selection of a clinically competent stem cell population based on their capacity of targeting brain tumors. A novel and generalizable organotypic slice platform to evaluate stem cell potential for targeting pediatric brain tumors is proposed to fill the gap in the current work flow of stem cell-based therapy. The organotypic slice platform has advantages of being mimic in vivo model, easier to manipulate to optimize parameters than in vivo models such as rodents and primates. This model serves as a framework to address the discrepancy between anticipated in vivo results and actual in vivo results, a critical barrier to timely progress in the field of the use of stem cells for the treatment of neurological disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.